Ceftaroline demonstrated excellent activity against MRSA with an MIC of 0.06 to ≤2 µg/mL. These isolates were collected from a single medical center in Athens, Greece, and appear to be derived from the same ancestor according to the molecular typing results. This favorable antimicrobial profile demonstrates that ceftaroline is a very promising anti-staphylococcal therapeutic option widely applicable in North America and Europe.

**Acknowledgement**

Supported by Forest Laboratories, Inc.

**References**

